|
Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients
RECRUITINGN/ASponsored by University Hospital, Clermont-Ferrand
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Clermont-Ferrand
Started2026-01-29
Est. completion2028-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07427537
Summary
This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or * Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles. Exclusion Criteria: * Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.), * History of stroke, * Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15/100), * Pain (NRS ≥ 4/10), * Pregnant or breastfeeding women, * Patients under guardianship, curatorship, deprived of liberty, or under legal protection
Conditions5
CancerCancer, LungColon NeoplasmLung CancerNeuropathy;Peripheral
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Clermont-Ferrand
Started2026-01-29
Est. completion2028-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07427537